Local donors give $300,000 to Israel cancer research

TORONTO — Longtime Israel Cancer Research Fund (ICRF) donors Carole and Howard Tanenbaum have pledged $300,000 to the organization over 10 years.

The funds come from the Howard and Carole Tanenbaum Family Charitable Foundation and will enable ICRF to award Carole Tanenbaum Woman of Action Business Award each year at its Woman of Action luncheon.

The luncheon, to be held on April 9 at the Royal York Hotel, recognizes the outstanding achievements of women in business, philanthropy and science.

TORONTO — Longtime Israel Cancer Research Fund (ICRF) donors Carole and Howard Tanenbaum have pledged $300,000 to the organization over 10 years.

The funds come from the Howard and Carole Tanenbaum Family Charitable Foundation and will enable ICRF to award Carole Tanenbaum Woman of Action Business Award each year at its Woman of Action luncheon.

The luncheon, to be held on April 9 at the Royal York Hotel, recognizes the outstanding achievements of women in business, philanthropy and science.

Carole Tanenbaum, creator of Carole Tanenbaum Vintage Collection, was the honoree in 2007.

 “Howard and I are longtime supporters of [ICRF}. This fund enables Israeli scientists to research and discover new ways of detecting and curing cancer,” she said.

“As a past honoree it is gratifying to continue to award outstanding women in business for their accomplishments and success. It is my hope that the [award] inspires all women to pursue their goals and follow their dreams.”

Money raised through the annual Women of Action luncheon goes to support a number of outstanding ICRF scientists in Israel. Each year, three or four scientists are selected as recipients of the ICRF Woman of Action grants

ICRF executive director Joy Wagner Arbus said that the donation, part of the ICRF’s major gifts initiative, can help increase cancer research.

“It is very meaningful because Carole is a past honoree, and the foundation believes in helping small charities because it catapults what [the charities] are able to do.”

ICRF’s scientific research has resulted in the development of such drugs as Gleevec, used in the treatment of chronic myelogenous leukemia, and Velcade, a drug developed based on Nobel Prize winning research by ICRF-funded scientists used in the treatment of multiple myeloma.

Author

Support Our Mission: Make a Difference!

The Canadian Jewish News is now a Registered Journalism Organization (RJO) as defined by the Canada Revenue Agency. To help support the valuable work we’re doing, we’re asking for individual monthly donations of at least $10. In exchange, you’ll receive tax receipts, a thank-you gift of our quarterly magazine delivered to your door, and our gratitude for helping continue our mission. If you have any questions about the donating process, please write to [email protected].

Support the Media that Speaks to You

Jewish Canadians deserve more than social media rumours, adversarial action alerts, and reporting with biases that are often undisclosed. The Canadian Jewish News proudly offers independent national coverage on issues that matter, sparking conversations that bridge generations. 

It’s an outlet you can count on—but we’re also counting on you.

Please support Jewish journalism that’s creative, innovative, and dedicated to breaking new ground to serve your community, while building on media traditions of the past 65 years. As a Registered Journalism Organization, contributions of any size are eligible for a charitable tax receipt.